BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22289491)

  • 41. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
    van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ;
    Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL.
    Szczepański T; van der Velden VH; Raff T; Jacobs DC; van Wering ER; Brüggemann M; Kneba M; van Dongen JJ
    Leukemia; 2003 Nov; 17(11):2149-56. PubMed ID: 14576730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Detection of minimal residual disease in childhood acute lymphoblastic leukemia by using real-time quantitative PCR].
    Zhang YT; Luo ZF; Fang JP; Guo HX; Huang K; Li CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1235-9. PubMed ID: 21129267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection and management of minimal residual disease in acute lymphoblastic leukemia.
    Schrappe M
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):244-9. PubMed ID: 25696862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
    Liu JY; Li ZG; Gao C; Cui L; Wu MY
    Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
    Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
    Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone RM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
    Jia YP; Liu GL; Zhang LP
    Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Shahkarami S; Mehrasa R; Younesian S; Yaghmaie M; Chahardouli B; Vaezi M; Rezaei N; Nikbakht M; Alimoghaddam K; Ghavamzadeh A; Tavakkoly-Bazzaz J; Ghaffari SH
    Ann Hematol; 2018 Apr; 97(4):585-595. PubMed ID: 29392424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Significance of minimal residual disease in lymphoid malignancies.
    Brüggemann M; Pott C; Ritgen M; Kneba M
    Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
    Brüggemann M; Schrauder A; Raff T; Pfeifer H; Dworzak M; Ottmann OG; Asnafi V; Baruchel A; Bassan R; Benoit Y; Biondi A; Cavé H; Dombret H; Fielding AK; Foà R; Gökbuget N; Goldstone AH; Goulden N; Henze G; Hoelzer D; Janka-Schaub GE; Macintyre EA; Pieters R; Rambaldi A; Ribera JM; Schmiegelow K; Spinelli O; Stary J; von Stackelberg A; Kneba M; Schrappe M; van Dongen JJ; ;
    Leukemia; 2010 Mar; 24(3):521-35. PubMed ID: 20033054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience.
    Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M
    Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PCR for monitoring of minimal residual disease in hematologic malignancy.
    Matsuda K; Sugano M; Honda T
    Clin Chim Acta; 2012 Jan; 413(1-2):74-80. PubMed ID: 22057038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.
    Izraeli S; Waldman D
    Acta Haematol; 2004; 112(1-2):34-9. PubMed ID: 15179003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes.
    Eckert C; Scrideli CA; Taube T; Songia S; Wellmann S; Manenti M; Seeger K; Biondi A; Cazzaniga G
    Leukemia; 2003 Dec; 17(12):2517-24. PubMed ID: 14562127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia.
    Hrabovsky S; Folber F; Horacek JM; Stehlikova O; Jelinkova H; Salek C; Doubek M;
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):743-748. PubMed ID: 30057330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.